On this page
TSC2
TSC complex subunit 2
TSC2 encodes tuberin, a tumour suppressor protein that regulates cell growth and division, with pathogenic variants causing tuberous sclerosis complex and related disorders. The TSC2 gene provides instructions for producing tuberin, a protein that works alongside hamartin to control cell proliferation and size.
TSC2 is located on the short (p) arm of chromosome 16, at band 16p13.3. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 16 in the library →Available at Jeen Health
Clinical tests that include this
Overview
The TSC2 gene encodes tuberin, a multifunctional tumour suppressor protein essential for controlling cell growth and proliferation. Located on chromosome 16, TSC2 produces a protein of 1,807 amino acids that forms a functional complex with hamartin, the protein encoded by the TSC1 gene. Together, these proteins act as critical gatekeepers, preventing cells from dividing too rapidly or growing to inappropriate sizes.
Pathogenic variants in TSC2 lead to tuberous sclerosis complex, a multisystem disorder affecting the brain, skin, kidneys, heart, and lungs. The protein's role extends beyond tumour suppression; tuberin participates in nutrient sensing, energy metabolism regulation, and cellular responses to growth signals. Understanding TSC2 function has become increasingly important in clinical genetics, as the gene appears on multiple NHS panels for conditions ranging from childhood epilepsy to adult kidney disease.
The TSC2 gene demonstrates autosomal dominant inheritance, meaning a single pathogenic variant in one copy is sufficient to cause disease. Because tuberin and hamartin work as obligate partners, disruption of either protein compromises the entire regulatory system. This partnership makes TSC2 variants particularly consequential - they don't merely reduce protein function incrementally but can disable a critical cellular control mechanism entirely.
What the gene does
The tuberin protein performs a central role in restraining cellular growth by working with hamartin to regulate downstream signalling networks. When cells receive signals promoting growth and proliferation, these proteins help determine whether conditions truly warrant expansion. Tuberin and hamartin accomplish this regulatory function by interacting with and influencing numerous other cellular proteins, forming a regulatory hub that integrates information about nutrient availability, energy status, and external growth signals.
Research suggests that the tuberin-hamartin partnership acts as a sensor mechanism, monitoring whether cells have adequate resources to support growth. When nutrients are plentiful and growth factors signal favourable conditions, the complex allows cells to proceed with anabolic activities including protein synthesis and proliferation. Conversely, under conditions of nutrient scarcity or cellular stress, the complex strengthens its inhibitory effects, directing cells toward more conservative, maintenance-oriented states. This dynamic switching ensures cells only commit resources to growth when appropriate.
The physical interaction between tuberin and hamartin occurs through tuberin's N-terminal region, encompassing approximately the first 400 amino acids. This binding interface must remain intact for the complex to function properly; disruption of this region typically leads to rapid degradation of tuberin even when the remainder of the protein structure remains undamaged. The stable partnership between these two proteins represents an essential prerequisite for their tumour suppressor activity.
Beyond its primary regulatory functions, evidence suggests tuberin influences cellular processes including adhesion, migration, and differentiation. The protein appears to coordinate how cells respond to low-oxygen conditions and may affect mitochondrial function and oxidative stress pathways. These additional activities help explain why pathogenic TSC2 variants produce diverse clinical manifestations spanning multiple organ systems. The protein's influence on neuronal development and synaptic plasticity likely underlies neurological features observed in tuberous sclerosis complex.
Tuberin's tumour suppressor capacity becomes particularly evident when both gene copies are inactivated within a single cell - a scenario that can occur through inheritance of one pathogenic variant plus acquisition of a somatic change affecting the remaining functional copy. Without any working tuberin, cells lose their normal growth restraints and may proliferate inappropriately, forming the hamartomas - benign tumour-like growths - characteristic of tuberous sclerosis complex across multiple organs.
Video: Genetics 101
Chromosome location
The TSC2 gene resides on the short arm of chromosome 16 at position 13.3 (16p13.3), a chromosomal region containing numerous genes involved in development and cellular regulation. The gene spans approximately 40 kilobases of genomic DNA and comprises 42 exons, which are transcribed and spliced to produce the mature messenger RNA encoding tuberin. The gene's substantial size and numerous exons create multiple opportunities for pathogenic variants to arise through various mutational mechanisms.
TSC2 sits immediately adjacent to the PKD1 gene, which encodes polycystin-1 and is responsible for autosomal dominant polycystic kidney disease. This close physical proximity occasionally results in contiguous gene deletion syndromes, where large chromosomal deletions eliminate both TSC2 and PKD1 simultaneously. Individuals with such deletions develop features of both tuberous sclerosis complex and polycystic kidney disease, typically experiencing more severe kidney involvement than those with isolated TSC2 variants. The genomic architecture in this region makes it vulnerable to rearrangements, and several recurrent deletion breakpoints have been characterised in clinical genetics laboratories.
Protein structure
Tuberin is organised into several distinct functional regions that collectively enable its tumour suppressor activity. The N-terminal region spanning approximately the first 400 amino acids is required for interaction with TSC1, establishing the physical partnership between tuberin and hamartin that is essential for complex stability and function. This region appears to contain multiple binding interfaces that anchor the two proteins together, and variants disrupting this domain typically result in rapid tuberin degradation even when the rest of the protein is intact.
The protein contains multiple disordered regions distributed throughout its length, including segments at amino acids 655-676, 930-964, 1083-1132, 1150-1174, 1331-1352, and 1364-1488. These intrinsically disordered regions lack fixed three-dimensional structure and often serve as flexible linkers between functional domains or as sites for post-translational modifications and protein-protein interactions. The presence of extensive disorder suggests tuberin may undergo significant conformational changes during its regulatory activities and may interact with multiple partner proteins beyond hamartin.
The Rap-GAP domain, located at amino acids 1531-1758 near the C-terminus, represents a critical functional element of the protein. This domain enables tuberin to influence the activity of small signalling molecules within cells, contributing to the protein's ability to regulate growth pathways. Pathogenic variants within this region often abolish tuberin's capacity to restrain cellular proliferation even when the protein remains stably expressed. A final disordered region spanning amino acids 1765-1793 caps the extreme C-terminus.
The multi-domain architecture of tuberin reflects its role as a regulatory hub integrating diverse cellular signals. Post-translational modifications including phosphorylation can occur across multiple regions, modulating tuberin's activity and stability in response to upstream kinases activated by growth factors and stress signals. Understanding this domain organisation helps explain why pathogenic variants distributed across the entire gene length can all produce similar loss-of-function consequences - disruption of any critical domain compromises the protein's overall tumour suppressor capacity.
Key variants
More than a thousand pathogenic and likely pathogenic variants have been documented in TSC2, making it one of the most extensively characterised disease genes in clinical genetics. The variant spectrum is notably heterogeneous, encompassing small insertions and deletions that disrupt the reading frame, nonsense variants that introduce premature stop codons, missense variants that alter critical amino acids, and larger deletions or duplications affecting one or more exons. This diversity reflects the gene's size and the multiple ways its function can be compromised.
Frameshift and nonsense variants together account for a substantial proportion of identified pathogenic changes in TSC2. These variants typically result in premature termination of protein synthesis, producing truncated tuberin molecules that lack essential functional domains or trigger nonsense-mediated decay of the mutant messenger RNA. Because tuberin requires its full-length structure to interact properly with hamartin and execute its regulatory activities, such truncating variants generally result in complete loss of function for the affected allele.
Missense variants - single amino acid substitutions - present more interpretive complexity, as not all amino acid changes disrupt protein function equally. Pathogenic missense variants tend to cluster in functionally critical regions, particularly the hamartin-binding domain and the Rap-GAP domain. Variants in these regions may destabilise the protein, prevent proper folding, abolish regulatory activity, or disrupt essential protein-protein interactions. Clinical laboratories employ multiple lines of evidence including computational predictions, functional studies, and segregation analysis to classify missense variants as pathogenic, benign, or of uncertain significance.
Large deletions encompassing multiple exons or the entire TSC2 gene represent another important variant class, particularly the contiguous gene deletions that also affect the adjacent PKD1 gene. Such structural variants require specialised detection methods beyond standard sequencing approaches. Mosaic variants - present in only a subset of an individual's cells - have been increasingly recognised in TSC2, and individuals with mosaic pathogenic variants may exhibit milder or more localised manifestations of tuberous sclerosis complex compared to those with constitutional variants affecting all cells.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.1060C>T | p.Gln354Ter | Pathogenic | ★★☆☆ | Tuberous sclerosis syndrome |
c.1074G>A | p.Trp358Ter | Pathogenic | ★★☆☆ | Tuberous sclerosis 2 |
c.1085T>C | p.Leu362Pro | Pathogenic/Likely pathogenic | ★★☆☆ | Tuberous sclerosis syndrome |
c.1096G>T | p.Glu366Ter | Pathogenic | ★★☆☆ | Tuberous sclerosis syndrome |
c.1108C>T | p.Gln370Ter | Pathogenic | ★★☆☆ | Tuberous sclerosis 2 |
c.1111C>T | p.Gln371Ter | Pathogenic | ★★☆☆ | Tuberous sclerosis syndrome |
c.1177G>T | p.Glu393Ter | Pathogenic | ★★☆☆ | Tuberous sclerosis 2 |
c.1195G>T | p.Glu399Ter | Pathogenic | ★★☆☆ | not provided |
c.1210C>T | p.Gln404Ter | Pathogenic | ★★☆☆ | Tuberous sclerosis syndrome |
c.1217_1218del | p.Arg406fs | Pathogenic | ★★☆☆ | Tuberous sclerosis 2 |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Pathogenic variants in TSC2 are primarily associated with tuberous sclerosis complex, a multisystem disorder characterised by the growth of hamartomas - benign tumour-like growths - in the brain, skin, kidneys, heart, lungs, and other organs. The condition shows highly variable expressivity, meaning the severity and specific manifestations differ substantially even among individuals with identical variants. Neurological features including epilepsy, intellectual disability, and autism spectrum disorder represent major sources of morbidity, whilst renal manifestations such as angiomyolipomas and cystic kidney disease can progress to kidney failure.
TSC2 variants also cause lymphangioleiomyomatosis, a destructive lung disease characterised by abnormal proliferation of smooth muscle-like cells within the lungs, leading to cyst formation, progressive loss of lung function, and recurrent pneumothorax. Lymphangioleiomyomatosis occurs almost exclusively in women and can present either in isolation (sporadic LAM) or as a manifestation of tuberous sclerosis complex. The female predominance suggests hormonal influences on disease expression, and many affected women experience symptom progression during pregnancy or with oestrogen exposure.
Somatic TSC2 variants - acquired changes occurring in specific tissues rather than inherited through the germline - can cause focal manifestations including focal cortical dysplasia type II, a localised brain malformation that frequently underlies drug-resistant epilepsy. Additionally, the gene is implicated in West syndrome, a severe infantile epileptic encephalopathy. The range of associated conditions reflects tuberin's fundamental importance across multiple developmental processes and organ systems, and the gene's appearance on numerous UK clinical panels underscores its relevance to diverse medical specialties from neurology to nephrology to dermatology.
Inheritance pattern
Conditions caused by pathogenic TSC2 variants typically follow autosomal dominant inheritance.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
UK clinical status
TSC2 holds significant status within the UK's National Health Service genomic medicine framework, appearing on at least fifteen PanelApp panels with green (high evidence) classification. The gene's inclusion in the Classical tuberous sclerosis panel and the dedicated Tuberous sclerosis panel reflects its central role in diagnosing this condition, whilst its presence on the Early onset or syndromic epilepsy panel acknowledges that seizures often represent the presenting feature prompting genetic investigation.
The gene appears on multiple developmental disorder panels including Intellectual disability, Fetal anomalies, and DDG2P (Developmental Disorders Genotype-Phenotype Database), recognising that tuberous sclerosis complex frequently manifests with neurodevelopmental challenges. Its inclusion on kidney-focused panels such as Cystic kidney disease and Unexplained kidney failure in young people highlights the renal manifestations that can dominate the clinical picture in some affected individuals, whilst membership in Primary lymphoedema and Pneumothorax - familial panels reflects the lymphatic and pulmonary involvement seen particularly in lymphangioleiomyomatosis.
Notably, TSC2 appears on several cancer susceptibility panels including Adult solid tumours cancer susceptibility, Childhood solid tumours cancer susceptibility, and related rare disease panels. Although tuberous sclerosis complex primarily involves benign tumours, the growths can be numerous, large, and cause significant morbidity; moreover, there is a recognised increased risk of renal cell carcinoma in affected individuals. The gene's classification within the ACMG Secondary Findings v3.2 list as a Tier 1 actionable gene means that UK laboratories performing genomic sequencing for other indications must consider reporting TSC2 pathogenic variants discovered incidentally, given the availability of medical interventions that can reduce morbidity.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Diet & lifestyle considerations
For individuals with pathogenic TSC2 variants, research suggests certain lifestyle considerations may support overall health, though these measures do not prevent or cure tuberous sclerosis complex and should complement rather than replace medical surveillance and treatment. Maintaining regular sleep patterns appears particularly relevant for those with seizure disorders, as sleep deprivation is a well-established seizure trigger in epilepsy. Establishing consistent bedtime routines and ensuring adequate sleep duration may help optimise seizure control in affected individuals.
Dietary considerations have received attention given tuberin's central role in nutrient sensing and growth regulation. Some research has explored whether ketogenic or modified Atkins diets - high-fat, low-carbohydrate dietary patterns that alter cellular metabolism - might influence disease manifestations, particularly seizure frequency. These specialised diets have shown efficacy in some individuals with drug-resistant epilepsy, though their implementation requires supervision by healthcare professionals experienced in metabolic dietary therapies. There is no evidence that any specific dietary pattern can reverse the underlying genetic condition or prevent tumour formation.
For women with TSC2-related lymphangioleiomyomatosis, clinical observations suggest that avoiding exogenous oestrogen exposure may be prudent, as the disease appears hormonally influenced and some studies indicate symptom progression with oestrogen-containing contraceptives or hormone replacement therapy. However, contraceptive decisions involve multiple factors beyond lymphangioleiomyomatosis risk, and women should discuss options comprehensively with their healthcare providers. Similarly, smoking cessation is particularly important for individuals with lung involvement, as tobacco smoke can accelerate lung damage.
Regular medical surveillance represents perhaps the most important 'lifestyle' consideration for individuals with TSC2 pathogenic variants. Evidence suggests that systematic monitoring for tumour growth and organ dysfunction enables earlier intervention, which may prevent complications. This includes periodic neuroimaging, kidney imaging, cardiac evaluation in children, and skin examination. Physical activity levels should be individualised based on cardiac and pulmonary status, with particular caution regarding activities that might precipitate pneumothorax in those with cystic lung disease.
Supplement considerations
There is no conclusive scientific evidence that any vitamin, mineral, or nutritional supplement can prevent tuberous sclerosis complex, reduce tumour burden, or modify disease progression in individuals with TSC2 pathogenic variants. The condition arises from fundamental disruption of cellular growth regulation, and no over-the-counter supplement has demonstrated capacity to compensate for loss of tuberin function. Individuals considering any supplement should discuss this with their healthcare provider before commencing use, particularly as supplements may interact with prescribed medications.
Some affected individuals and families have inquired about antioxidant supplements such as vitamin E, selenium, or N-acetylcysteine based on research suggesting oxidative stress may contribute to certain manifestations of tuberous sclerosis complex. Whilst cellular studies have shown altered oxidative metabolism in tuberin-deficient cells, there is insufficient evidence from human clinical trials to recommend antioxidant supplementation as a disease-modifying strategy. Moreover, high-dose antioxidant supplementation carries potential risks and can interfere with certain treatments.
Vitamin D supplementation warrants consideration not as a disease-specific intervention but because individuals with tuberous sclerosis complex may have increased risk of vitamin D insufficiency due to seizure medications (particularly enzyme-inducing anticonvulsants), reduced sun exposure related to photosensitivity or mobility limitations, or kidney dysfunction affecting vitamin D metabolism. Vitamin D status can be assessed through blood testing, and supplementation guided by measured levels and clinical need. This represents standard supportive care rather than targeted therapy for the underlying genetic condition.
Similarly, individuals taking mTOR inhibitors such as sirolimus or everolimus - medications that directly target pathways disrupted by TSC2 variants - may require nutritional monitoring and support, but specific supplement recommendations should come from the prescribing specialist familiar with the individual's complete medical picture. Some clinical trials have explored combination approaches pairing pharmaceutical mTOR inhibition with various supplements, but such strategies remain investigational and should only be pursued within formal research protocols. The cornerstone of management for TSC2-related conditions remains evidence-based medical therapy and surveillance rather than supplementation.
Frequently asked questions
What is the difference between TSC1 and TSC2?
TSC1 and TSC2 encode two proteins (hamartin and tuberin) that work together as a complex to regulate cell growth. Pathogenic variants in either gene can cause tuberous sclerosis complex with similar features, though the clinical presentation and severity may show some variation between the two.
Can you have tuberous sclerosis complex without a TSC2 variant?
Yes, some cases result from pathogenic variants in TSC1 rather than TSC2. Additionally, some individuals meet clinical diagnostic criteria without an identifiable variant in either gene, possibly due to mosaicism or variants in regulatory regions not captured by standard testing.
Why does TSC2 primarily affect certain organs like the brain and kidneys?
Tuberin regulates cellular growth pathways that are particularly active in brain, kidney, skin, and lung tissues. These organs appear especially vulnerable to hamartoma formation when growth regulation is disrupted, though the precise reasons for organ-specific susceptibility remain incompletely understood and likely involve tissue-specific growth factor environments and cellular stress responses.
Is genetic testing for TSC2 available on the NHS?
Yes, TSC2 genetic testing is available through the NHS for individuals meeting clinical criteria for tuberous sclerosis complex or related conditions. Testing typically occurs following referral to clinical genetics services and may include sequencing and deletion/duplication analysis to detect various types of pathogenic variants.
What does it mean that TSC2 is autosomal dominant?
Autosomal dominant inheritance means a pathogenic variant in just one copy of TSC2 (out of the two copies everyone carries) is sufficient to cause tuberous sclerosis complex. Each child of an affected individual has a 50% chance of inheriting the variant, though many cases represent new variants not inherited from either parent.
Are there targeted treatments for conditions caused by TSC2 variants?
Yes, mTOR inhibitors such as everolimus have received regulatory approval for specific TSC2-related manifestations including renal angiomyolipomas, subependymal giant cell astrocytomas, and TSC-associated epilepsy. These medications work by directly inhibiting signalling pathways that become overactive when tuberin function is lost, though they manage rather than cure the condition.
References
- Chorianopoulos D, Stratakos G. Lymphangioleiomyomatosis and tuberous sclerosis complex. Lung. 2008. PMID: 18408969
- Adam MP, Bick S, Mirzaa GM. Tuberous Sclerosis Complex. 1993. PMID: 20301399